Top

Published in:

Open Access 01-12-2019 | Sorafenib | Retraction Note

Retraction Note to: IL‑2 augments the sorafenib‑induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway

Authors: Xiaoyan Ding, Wei Sun, Jinglong Chen

Published in: Cancer Cell International | Issue 1/2019

Excerpt

The editor has retracted this article [1] because Figures 2 and 4 contain duplicated and modified figures from [2‐4]. The data reported in this article are therefore unreliable.

Figure 2m in [1] contains figures that have been duplicated and modified from Fig. 2a in [2].
Figure 2 m in [1] contains figures that have been duplicated and modified from Fig. 6j in [3].
Figure 4g in [1] is identical to Fig. 4f in [4].
Figure 4i in [1] contains figures that are identical to Fig. 4h in [4].

…

Ding X, Sun W, Chen J. IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway. Cancer Cell Int. 2018;18:176. https://doi.org/10.1186/s12935-018-0671-3.CrossRefPubMedPubMedCentral

Wei R, Cao J, Yao S. Matrine promotes liver cancer cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways. Cell Stress Chaperones. 2018;23:1295. https://doi.org/10.1007/s12192-018-0937-7.CrossRefPubMedPubMedCentral

Jieensinue S, Zhu H, Li G, et al. Tanshinone IIA reduces SW837 colorectal cancer cell viability via the promotion of mitochondrial fission by activating JNK-Mff signaling pathways. BMC Cell Biol. 2018;19:21. https://doi.org/10.1186/s12860-018-0174-z.CrossRefPubMedPubMedCentral

Zhang L, Li S, Wang R, Chen C, Ma W, Cai H. Cytokine augments the sorafenib-induced apoptosis in Huh7 liver cancer cell by inducing mitochondrial fragmentation and activating MAPK-JNK signalling pathway. Biomed Pharmacother. 2019;110:213–23. https://doi.org/10.1016/j.biopha.2018.11.037.CrossRefPubMed

Title: Retraction Note to: IL‑2 augments the sorafenib‑induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway
Authors: Xiaoyan Ding
Wei Sun
Jinglong Chen
Publication date: 01-12-2019
Publisher: BioMed Central
Keyword: Sorafenib
Published in: Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-019-1083-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2019

Combined analysis and validation for DNA methylation and gene expression profiles associated with prostate cancer

New insights into the association between AXIN2 148 C/T, 1365 C/T, and rs4791171 A/G variants and cancer risk

RETRACTED ARTICLE: Degradation of long non-coding RNA-CIR decelerates proliferation, invasion and migration, but promotes apoptosis of osteosarcoma cells

LINC00511 accelerated the process of gastric cancer by targeting miR-625-5p/NFIX axis

Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization

ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer